Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome (Q40566975)
Jump to navigation
Jump to search
scientific article published on 23 January 2003
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome |
scientific article published on 23 January 2003 |
Statements
1 reference
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome (English)
1 reference
Eva Cavallin-Ståhl
1 reference
Hans Hagberg
1 reference
Jeanette Lundin
1 reference
Roland Repp
1 reference
Susanne Fredén
1 reference
Gunnar Juliusson
1 reference
Eija Rosenblad
1 reference
Geir Tjønnfjord
1 reference
Tom Wiklund
1 reference
Anders Osterborg
1 reference
23 January 2003
1 reference
1 reference
101
1 reference
11
1 reference
4267-4272
1 reference
Identifiers
1 reference
1 reference